Zim Laboratories Ltd
Incorporated in 1989, Zim Laboratories
Ltd manufactures formulation drugs and
pre formulation ingredients in India and
markets and sells these within and out
side India[1]
- Market Cap ₹ 597 Cr.
- Current Price ₹ 122
- High / Low ₹ 153 / 74.0
- Stock P/E 37.3
- Book Value ₹ 45.0
- Dividend Yield 0.00 %
- ROCE 17.3 %
- ROE 13.7 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.72 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 7.84% over past five years.
- Promoter holding is low: 33.3%
- Company has a low return on equity of 9.40% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
266 | 268 | 235 | 272 | 332 | 274 | 304 | 329 | 397 | 353 | |
278 | 238 | 203 | 238 | 289 | 255 | 267 | 292 | 345 | 313 | |
Operating Profit | -12 | 30 | 32 | 34 | 43 | 20 | 37 | 38 | 51 | 40 |
OPM % | -4% | 11% | 14% | 13% | 13% | 7% | 12% | 12% | 13% | 11% |
2 | -2 | 5 | 9 | 2 | 5 | -3 | 5 | 6 | 4 | |
Interest | 10 | 14 | 10 | 9 | 11 | 13 | 11 | 8 | 6 | 6 |
Depreciation | 7 | 9 | 9 | 10 | 11 | 13 | 15 | 15 | 16 | 16 |
Profit before tax | -27 | 5 | 18 | 24 | 23 | -1 | 9 | 19 | 36 | 22 |
Tax % | 19% | 5% | -6% | 24% | 30% | 216% | 35% | 33% | 30% | |
-22 | 5 | 19 | 18 | 16 | 2 | 6 | 13 | 25 | 16 | |
EPS in Rs | 3.31 | 0.36 | 1.15 | 2.67 | 5.13 | 3.29 | ||||
Dividend Payout % | 0% | 16% | 4% | 4% | 5% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 13% |
TTM: | -11% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 143% |
TTM: | -34% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 24% |
3 Years: | 57% |
1 Year: | 54% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 9% |
Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 |
Reserves | 86 | 91 | 110 | 128 | 135 | 136 | 141 | 154 | 145 | 171 |
93 | 96 | 81 | 81 | 77 | 90 | 82 | 53 | 62 | 62 | |
78 | 61 | 60 | 80 | 96 | 81 | 81 | 112 | 79 | 78 | |
Total Liabilities | 265 | 256 | 259 | 297 | 325 | 323 | 320 | 335 | 335 | 359 |
87 | 92 | 89 | 94 | 101 | 111 | 103 | 103 | 107 | 119 | |
CWIP | 6 | 3 | 4 | 8 | 13 | 10 | 10 | 11 | 26 | 41 |
Investments | 0 | 0 | 0 | 0 | 5 | 8 | 8 | 8 | 8 | 8 |
172 | 161 | 166 | 195 | 206 | 194 | 199 | 213 | 193 | 191 | |
Total Assets | 265 | 256 | 259 | 297 | 325 | 323 | 320 | 335 | 335 | 359 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|
22 | 32 | 37 | 37 | 21 | 32 | 47 | 35 | ||
-12 | -7 | -26 | -23 | -19 | -6 | -14 | -35 | ||
-10 | -25 | -10 | -15 | -2 | -26 | -33 | 1 | ||
Net Cash Flow | -0 | -0 | 1 | -1 | 0 | 0 | -0 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 111 | 120 | 137 | 119 | 99 | 84 | 77 | 90 | 81 |
Inventory Days | 104 | 88 | 108 | 134 | 126 | 144 | 125 | 171 | 99 |
Days Payable | 144 | 109 | 137 | 172 | 165 | 168 | 150 | 186 | 109 |
Cash Conversion Cycle | 71 | 99 | 108 | 81 | 61 | 60 | 52 | 75 | 71 |
Working Capital Days | 108 | 111 | 127 | 103 | 85 | 107 | 113 | 96 | 95 |
ROCE % | 13% | 14% | 13% | 15% | 5% | 10% | 12% | 17% |
Documents
Announcements
-
Reply To The Clarification Sought On Movement Of Price
6h - The Company at this moment does not have any information or announcement that is required to be made which may have bearing on the price/volume …
-
Clarification sought from Zim Laboratories Ltd
21h - Exchange has sought clarification from Zim Laboratories Ltd on April 25, 2024 with reference to significant movement in price, in order to ensure that investors …
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
- Reply To The Clarification Sought On Increase In Trading Volume Of The Shares Of The Company 2d
-
Clarification sought from Zim Laboratories Ltd
2d - Exchange has sought clarification from Zim Laboratories Ltd on April 24, 2024, with reference to Movement in Volume.
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2019TranscriptNotesPPT
-
Dec 2018TranscriptNotesPPT
Business Overview:[1]
ZLL is a EU-GMP, WHOGMP, NSF/ANSI 455-2 certified research-driven pharmaceutical company that develops, manufactures and supplies generic products in the oral solid dosage forms, both as pre-formulation intermediates ad finished formulations for certain key therapeutic segments. It offers both pharmaceutical and nutraceutical products. Company has an in-house R&D capabilities to offer a range of non-infringing drug
delivery solutions based on process technologies